|
|
| Line 3: |
Line 3: |
| | <StructureSection load='4az3' size='340' side='right'caption='[[4az3]], [[Resolution|resolution]] 2.04Å' scene=''> | | <StructureSection load='4az3' size='340' side='right'caption='[[4az3]], [[Resolution|resolution]] 2.04Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4az3]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4AZ3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4AZ3 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4az3]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4AZ3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4AZ3 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CD:CADMIUM+ION'>CD</scene>, <scene name='pdbligand=S35:(3S)-3-({[1-(2-FLUOROPHENYL)-5-{[(2R)-2-HYDROXY-3,3-DIMETHYLBUTYL]OXY}-1H-PYRAZOL-3-YL]CARBONYL}AMINO)-3-(2-METHYLPHENYL)PROPANOIC+ACID'>S35</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.04Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1ivy|1ivy]], [[4az0|4az0]]</div></td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CD:CADMIUM+ION'>CD</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=S35:(3S)-3-({[1-(2-FLUOROPHENYL)-5-{[(2R)-2-HYDROXY-3,3-DIMETHYLBUTYL]OXY}-1H-PYRAZOL-3-YL]CARBONYL}AMINO)-3-(2-METHYLPHENYL)PROPANOIC+ACID'>S35</scene></td></tr> |
| - | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/Carboxypeptidase_C Carboxypeptidase C], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.16.5 3.4.16.5] </span></td></tr>
| + | |
| | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4az3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4az3 OCA], [https://pdbe.org/4az3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4az3 RCSB], [https://www.ebi.ac.uk/pdbsum/4az3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4az3 ProSAT]</span></td></tr> | | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4az3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4az3 OCA], [https://pdbe.org/4az3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4az3 RCSB], [https://www.ebi.ac.uk/pdbsum/4az3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4az3 ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Disease == | | == Disease == |
| - | [[https://www.uniprot.org/uniprot/PPGB_HUMAN PPGB_HUMAN]] Defects in CTSA are the cause of galactosialidosis (GSL) [MIM:[https://omim.org/entry/256540 256540]]. A lysosomal storage disease associated with a combined deficiency of beta-galactosidase and neuraminidase, secondary to a defect in cathepsin A. All patients have clinical manifestations typical of a lysosomal disorder, such as coarse facies, cherry red spots, vertebral changes, foam cells in the bone marrow, and vacuolated lymphocytes. Three phenotypic subtypes are recognized. The early infantile form is associated with fetal hydrops, edema, ascites, visceromegaly, skeletal dysplasia, and early death. The late infantile type is characterized by hepatosplenomegaly, growth retardation, cardiac involvement, and a normal or mildly affected mental state. The juvenile/adult form is characterized by myoclonus, ataxia, angiokeratoma, mental retardation, neurologic deterioration, absence of visceromegaly, and long survival.<ref>PMID:1756715</ref> <ref>PMID:8514852</ref> <ref>PMID:8968752</ref> <ref>PMID:10944848</ref>
| + | [https://www.uniprot.org/uniprot/PPGB_HUMAN PPGB_HUMAN] Defects in CTSA are the cause of galactosialidosis (GSL) [MIM:[https://omim.org/entry/256540 256540]. A lysosomal storage disease associated with a combined deficiency of beta-galactosidase and neuraminidase, secondary to a defect in cathepsin A. All patients have clinical manifestations typical of a lysosomal disorder, such as coarse facies, cherry red spots, vertebral changes, foam cells in the bone marrow, and vacuolated lymphocytes. Three phenotypic subtypes are recognized. The early infantile form is associated with fetal hydrops, edema, ascites, visceromegaly, skeletal dysplasia, and early death. The late infantile type is characterized by hepatosplenomegaly, growth retardation, cardiac involvement, and a normal or mildly affected mental state. The juvenile/adult form is characterized by myoclonus, ataxia, angiokeratoma, mental retardation, neurologic deterioration, absence of visceromegaly, and long survival.<ref>PMID:1756715</ref> <ref>PMID:8514852</ref> <ref>PMID:8968752</ref> <ref>PMID:10944848</ref> |
| | == Function == | | == Function == |
| - | [[https://www.uniprot.org/uniprot/PPGB_HUMAN PPGB_HUMAN]] Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins.<ref>PMID:1907282</ref>
| + | [https://www.uniprot.org/uniprot/PPGB_HUMAN PPGB_HUMAN] Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins.<ref>PMID:1907282</ref> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 26: |
Line 25: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Carboxypeptidase C]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Buning, C]] | + | [[Category: Buning C]] |
| - | [[Category: Hiss, K]] | + | [[Category: Hiss K]] |
| - | [[Category: Horstick, G]] | + | [[Category: Horstick G]] |
| - | [[Category: Huebschle, T]] | + | [[Category: Huebschle T]] |
| - | [[Category: Kannt, A]] | + | [[Category: Kannt A]] |
| - | [[Category: Kohlmann, M]] | + | [[Category: Kohlmann M]] |
| - | [[Category: Kroll, K]] | + | [[Category: Kroll K]] |
| - | [[Category: Linz, D]] | + | [[Category: Linz D]] |
| - | [[Category: Linz, W]] | + | [[Category: Linz W]] |
| - | [[Category: Olpp, T]] | + | [[Category: Olpp T]] |
| - | [[Category: Pernerstorfer, J]] | + | [[Category: Pernerstorfer J]] |
| - | [[Category: Ruetten, H]] | + | [[Category: Ruetten H]] |
| - | [[Category: Ruf, S]] | + | [[Category: Ruf S]] |
| - | [[Category: Sadowski, T]] | + | [[Category: Sadowski T]] |
| - | [[Category: Schmidt, T]] | + | [[Category: Schmidt T]] |
| - | [[Category: Schreuder, H]] | + | [[Category: Schreuder H]] |
| - | [[Category: Wirth, K]] | + | [[Category: Wirth K]] |
| - | [[Category: Carboxypeptidase]]
| + | |
| - | [[Category: Cardiovascular]]
| + | |
| - | [[Category: Drug discovery]]
| + | |
| - | [[Category: Hydrolase]]
| + | |
| Structural highlights
Disease
PPGB_HUMAN Defects in CTSA are the cause of galactosialidosis (GSL) [MIM:256540. A lysosomal storage disease associated with a combined deficiency of beta-galactosidase and neuraminidase, secondary to a defect in cathepsin A. All patients have clinical manifestations typical of a lysosomal disorder, such as coarse facies, cherry red spots, vertebral changes, foam cells in the bone marrow, and vacuolated lymphocytes. Three phenotypic subtypes are recognized. The early infantile form is associated with fetal hydrops, edema, ascites, visceromegaly, skeletal dysplasia, and early death. The late infantile type is characterized by hepatosplenomegaly, growth retardation, cardiac involvement, and a normal or mildly affected mental state. The juvenile/adult form is characterized by myoclonus, ataxia, angiokeratoma, mental retardation, neurologic deterioration, absence of visceromegaly, and long survival.[1] [2] [3] [4]
Function
PPGB_HUMAN Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins.[5]
Publication Abstract from PubMed
Cathepsin A (CatA) is a serine carboxypeptidase distributed between lysosomes, cell membrane, and extracellular space. Several peptide hormones including bradykinin and angiotensin I have been described as substrates. Therefore, the inhibition of CatA has the potential for beneficial effects in cardiovascular diseases. Pharmacological inhibition of CatA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt-induced hypertension. However, so far no small molecule inhibitors of CatA with oral bioavailability have been described to allow further pharmacological profiling. In our work we identified novel beta-amino acid derivatives as inhibitors of CatA after a HTS analysis based on a project adapted fragment approach. The new inhibitors showed beneficial ADME and pharmacokinetic profiles, and their binding modes were established by X-ray crystallography. Further investigations led to the identification of a hitherto unknown pathophysiological role of CatA in cardiac hypertrophy. One of our inhibitors is currently undergoing phase I clinical trials.
Novel beta-Amino Acid Derivatives as Inhibitors of Cathepsin A.,Ruf S, Buning C, Schreuder H, Horstick G, Linz W, Olpp T, Pernerstorfer J, Hiss K, Kroll K, Kannt A, Kohlmann M, Linz D, Hubschle T, Rutten H, Wirth K, Schmidt T, Sadowski T J Med Chem. 2012 Sep 13;55(17):7636-49. Epub 2012 Aug 16. PMID:22861813[6]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Zhou XY, Galjart NJ, Willemsen R, Gillemans N, Galjaard H, d'Azzo A. A mutation in a mild form of galactosialidosis impairs dimerization of the protective protein and renders it unstable. EMBO J. 1991 Dec;10(13):4041-8. PMID:1756715
- ↑ Shimmoto M, Fukuhara Y, Itoh K, Oshima A, Sakuraba H, Suzuki Y. Protective protein gene mutations in galactosialidosis. J Clin Invest. 1993 Jun;91(6):2393-8. PMID:8514852 doi:http://dx.doi.org/10.1172/JCI116472
- ↑ Zhou XY, van der Spoel A, Rottier R, Hale G, Willemsen R, Berry GT, Strisciuglio P, Morrone A, Zammarchi E, Andria G, d'Azzo A. Molecular and biochemical analysis of protective protein/cathepsin A mutations: correlation with clinical severity in galactosialidosis. Hum Mol Genet. 1996 Dec;5(12):1977-87. PMID:8968752
- ↑ Takiguchi K, Itoh K, Shimmoto M, Ozand PT, Doi H, Sakuraba H. Structural and functional study of K453E mutant protective protein/cathepsin A causing the late infantile form of galactosialidosis. J Hum Genet. 2000;45(4):200-6. PMID:10944848 doi:10.1007/s100380070027
- ↑ Galjart NJ, Morreau H, Willemsen R, Gillemans N, Bonten EJ, d'Azzo A. Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function. J Biol Chem. 1991 Aug 5;266(22):14754-62. PMID:1907282
- ↑ Ruf S, Buning C, Schreuder H, Horstick G, Linz W, Olpp T, Pernerstorfer J, Hiss K, Kroll K, Kannt A, Kohlmann M, Linz D, Hubschle T, Rutten H, Wirth K, Schmidt T, Sadowski T. Novel beta-Amino Acid Derivatives as Inhibitors of Cathepsin A. J Med Chem. 2012 Sep 13;55(17):7636-49. Epub 2012 Aug 16. PMID:22861813 doi:http://dx.doi.org/10.1021/jm300663n
|
